

<https://helda.helsinki.fi>

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

Farkkila, Anniina

2017

Farkkila , A , Haltia , U-M , Tapper , J , McConechy , M K , Huntsman , D G & Heikinheimo , M 2017 , ' Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary ' , Annals of Medicine , vol. 49 , no. 5 , pp. 435-447 . <https://doi.org/10.1080/07853890.2017.1294760>

<http://hdl.handle.net/10138/235608>

<https://doi.org/10.1080/07853890.2017.1294760>

unspecified

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



Annals of Medicine

Annals of Medicine

<http://tandfonline.com/loi/iann20>ISSN: 0785-3890 (Print) 1365-2060 (Online) Journal homepage: <http://www.tandfonline.com/loi/iann20>

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

Anniina Färkkilä, Ulla-Maija Haltia, Johanna Tapper, Melissa K. McConechy, David G. Huntsman & Markku Heikinheimo

To cite this article: Anniina Färkkilä, Ulla-Maija Haltia, Johanna Tapper, Melissa K. McConechy, David G. Huntsman & Markku Heikinheimo (2017) Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary, *Annals of Medicine*, 49:5, 435-447, DOI: 10.1080/07853890.2017.1294760

To link to this article: <http://dx.doi.org/10.1080/07853890.2017.1294760>



Accepted author version posted online: 13 Feb 2017.
Published online: 06 Mar 2017.



Submit your article to this journal [↗](#)



Article views: 175



View related articles [↗](#)



View Crossmark data [↗](#)

REVIEW ARTICLE

Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary

Anniina Färkkilä^{a,b}, Ulla-Maija Haltia^{a,b}, Johanna Tapper^a, Melissa K. McConechy^c, David G. Huntsman^{d,e} and Markku Heikinheimo^{b,f}

^aDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ^bChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; ^cDepartment of Human Genetics, Research Institute of the McGill University Health Centre, McGill University, Montreal, Canada; ^dDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; ^eDepartment of Molecular Oncology, British Columbia Cancer Agency, Vancouver, Canada; ^fDepartment of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, USA

ABSTRACT

Adult-type granulosa cell tumor is a clinically and molecularly unique subtype of ovarian cancer. These tumors originate from the sex cord stromal cells of the ovary and represent 3–5% of all ovarian cancers. The majority of adult-type granulosa cell tumors are diagnosed at an early stage with an indolent prognosis. Surgery is the cornerstone for the treatment of both primary and relapsed tumor, while chemotherapy is applied only for advanced or non-resectable cases. Tumor stage is the only factor consistently associated with prognosis. However, every third of the patients relapse, typically in 4–7 years from diagnosis, leading to death in 50% of these patients. Anti-Müllerian Hormone and inhibin B are currently the most accurate circulating biomarkers. Adult-type granulosa cell tumors are molecularly characterized by a pathognomonic somatic missense point mutation 402C->G (C134W) in the transcription factor FOXL2. The FOXL2 402C->G mutation leads to increased proliferation and survival of granulosa cells, and promotes hormonal changes. Histological diagnosis of adult-type granulosa cell tumor is challenging, therefore testing for the FOXL2 mutation is crucial for differential diagnosis. Large international collaborations utilizing molecularly defined cohorts are essential to improve and validate new treatment strategies for patients with high-risk or relapsed adult-type granulosa cell tumor.

KEY MESSAGES:

- Adult-type granulosa cell tumor is a unique ovarian cancer with an indolent, albeit unpredictable disease course.
- Adult-type granulosa cell tumors harbor a pathognomonic somatic missense mutation in transcription factor FOXL2.
- The key challenges in the treatment of patients with adult-type granulosa cell tumor lie in the identification and management of patients with high-risk or relapsed disease.

ARTICLE HISTORY

Received 4 November 2016
Revised 8 February 2017
Accepted 9 February 2017

KEYWORDS

Adult-type granulosa cell tumor; ovarian cancer; FOXL2; prognostic factors; treatment; follow-up

Introduction

Granulosa cell tumour (GCT) of the ovary is a rare subtype of ovarian cancer originating from the sex-cord stromal component of the ovary (1). The incidence of GCTs is 0.6–0.8/100,000, and it accounts for 3–5% of all ovarian malignancies (2). GCTs present with two clinically and molecularly distinct subtypes; the juvenile and the adult type (1). Adult-type GCT (AGCT) is the more common, whereas the juvenile comprises only 5% of all GCTs. Juvenile GCT is generally diagnosed at early stage in children and adolescents, and presents with a favorable prognosis, although at advanced stages the clinical course may be more aggressive (3). Although extremely uncommon, the

juvenile type can be found in adults and the adult type in children. AGCTs are usually diagnosed in perimenopausal women between ages 50 and 54, although it can occur throughout the adult woman's lifespan. AGCT is a unique subtype of ovarian cancer with distinct clinical and molecular features. This review focuses on the current view on the pathogenesis and treatment of AGCTs of the ovary.

Presentation and diagnosis

Clinical presentation

AGCTs are clinically distinct ovarian cancers due to their prominent hormonal activity and production of

estrogen and inhibins (1). The most common presenting symptoms are abnormal vaginal bleeding (45%), and abdominal pain or bloating (10–20%) (4). In premenopausal patients, AGCT typically cause irregular bleeding, amenorrhea and more infrequently infertility (4). In postmenopausal patients, abnormal vaginal bleeding associated with a unilateral ovarian mass is the most common clinical presentation. Ascites is rarely present in the primary diagnosis. In 8–15% of the cases, the tumor presents with a spontaneous rupture manifesting as acute abdominal pain and hemoperitoneum (4,5). In ultrasonography, AGCT characteristically presents with a cystic to solid ovarian mass with high vasculature (6). Typically, these patients also have an abnormally thick endometrium, pathological examination may reveal endometrial hyperplasia in 26–38% and synchronous endometrial cancer is diagnosed in 6–7% of the patients (4,7).

Prognosis

Outcomes

Due to the slow growth and distinguishable hormonal symptoms, AGCTs are generally diagnosed at an early stage. The majority (50–80%) are diagnosed at stage Ia (4,5,8,9), in which the tumor is completely inside the ovarian capsule, and no tumor cells are found outside the ovary (10). The second most common (~30%) is stage Ic, in which tumor cells infiltrate through the ovarian capsule, or the capsule is ruptured either spontaneously or due to iatrogenic reasons. Generally, AGCTs have a remarkably indolent behavior compared to other ovarian malignancies. However, the reported outcomes have significantly varied between cohorts; the reported 5-year overall survival rates between 61% and 95% and disease-specific survival rates between 67% and 99% have been reported (Table 1). Likewise, the recurrence rates may vary between 6% and 48%. However, in a validated large cohort, patients have excellent outcomes, with the overall survival comparable to a general age-matched population; the 5- and 10-year overall survival rates are 98% and 84%, respectively (11). In addition, in advanced stage (III–IV), molecularly defined AGCTs are extremely uncommon.

Even though most early stage AGCT patients experience an excellent outcome, every third patient will eventually develop a tumor relapse, and this will lead to death in 50–80% of the relapsed patients (4,11,12). Thus, a unique challenge in the treatment of AGCT patients lies in the long latency to disease relapse; the typical time to relapse varies between 4 and 8 years

(4,8,13) the median being 7.2 years in a histologically and molecularly defined large AGCT cohorts (11). AGCT may, however relapse even after 30–40 years from diagnosis (14), warranting for life-long surveillance of especially in the high-risk patients. The cellular mechanisms of latency and late relapse have not been established in AGCTs, however they may include mechanisms of tumor dormancy similarly to those reported in breast cancer (15).

Prognostic factors

Multiple clinical and histological prognostic factors have been investigated for their role in AGCT prognostics, however the results have been inconclusive and varied significantly between cohorts. Tumor stage is the only consistent factor that has been linked to tumor relapse and survival (4,8,16). Among the stage I patients, those with tumor penetrating the ovarian capsule or tumor rupture (stage Ic) have a significantly increased risk of disease relapse (9,17). Consistently, rupture of the tumor capsule has been implicated as an adverse prognostic indicator, also in stage I AGCTs (17–19). Interestingly, in a recent study of verified AGCTs, there was no difference in the risk of relapse between surgically or spontaneously ruptured tumors (17). The identification of risk factors among stage I patients is the clinically most important determinant since stage I patients form the majority of AGCT patients. Thus, future clinical and scientific efforts need to be concentrated on how to identify and manage early-stage AGCT patients at increased risk of relapse. In addition, some studies have reported postoperative residual tumor (19) as well as large tumor size as an adverse prognostic factors (8,18). However, the adjustment of tumor stage is not clearly defined in these studies, and some studies show inconsistent results (12,13,20). Further, it is not clear whether patient age at diagnosis affects the prognosis (4,20), whereas parity and reproductive status do not seem to influence outcome of AGCTs (4).

Regarding histopathological prognostic factors, the different histological subtypes have not been associated with prognosis (19), whereas high mitotic activity and nuclear atypia have been shown to predict worse prognosis (21,22). Multiple histological prognostic factors, e.g. Ki67, p53, members of the epidermal growth factor receptor (EGFR) family, and transcription factor GATA4 have been evaluated (22,23), but their clinical applicability remains unclear. The potential histopathological prognostic factors have not yet been validated in independent validated cohorts limiting their use in clinical decision-making.

Table 1. Retrospective studies reporting the prognosis of AGCT patients.

| # | 1 st author | Journal | PMID | Pub Yr | # Pt | Study period | Follow-up time Mo Median (range) | DSS 5-year % | DSS 10-year % | OS 5-year % | OS 10-year % | Recurrences % | Histological verification | false Dg % | Notes |
|----|------------------------|------------------------|----------|--------|------|--------------|----------------------------------|--------------|---------------|-------------|--------------|---------------|---------------------------|------------|---|
| 1 | Dinnerstein | Obstet Gynecol | 4296441 | 1968 | 47 | 1926-1966 | ND | ND | ND | ND | ND | 36b | Yes | ND | Granulosa and Theca cell tumors Only stage I disease median OS 117 Mo (range 19-334) |
| 2 | Novak | Obstet Gynecol | 4329789 | 1974 | 71 | 1942-1970 | ND | 67 | ND | 61 | ND | ND | Yes | ND | |
| 3 | Stenwig | Gynecol Oncol | 437566 | 1979 | 118 | 1932-1970 | ND | 82 | ND | 80 | 66 | 21 | Yes | ND | |
| 4 | Malmström | Gynecol Oncol | 8307501 | 1994 | 54 | 1953-1987 | ND | ND | ND | 90 | ND | 9 | Yes | 25 | |
| 5 | Miller | Cancer | 9149022 | 1997 | 70 | 1958-1993 | 98 | ND | ND | ND | ND | 27 | Yes | 35.8 | |
| 6 | Pautler | Int J Gynecol Cancer | 12795806 | 1997 | 45 | 1976-1993 | 65 (1-324) | ND | ND | 77 | 67 | 33 | Yes | ND | |
| 7 | Savage | Clin Oncol | 9764376 | 1998 | 62 | 1969-1995 | ND | ND | ND | ND | ND | 37 | Yes | ND | |
| 8 | Cronje | Am J Obstet Gynecol | 9988794 | 1999 | 97 | 1942-1998a | ND | 89 | 77 | ND | ND | 25 | Yes | 33 | |
| 9 | Lauszus | Gynecol Oncol | 1371138 | 2001 | 37 | 1962-1996 | 96 (8-312) | ND | ND | 93 | 84 | 35 | Yes | ND | 17 (70%) FOXL2 mutation positive 18 (35%) FOXL2 mutation positive 3 patients included without histological verification Only stage I patients 256 FOXL2 mutation positive AGCTs |
| 10 | Abu-Rustum | Gynecol Oncol | 16537089 | 2006 | 64 | 1971-2005 | ND | ND | ND | ND | ND | 48 | Yes | ND | |
| 11 | Auranen | Int J Gynecol Cancer | 17374124 | 2007 | 35 | 1970-2003 | 135 (19-334) | ND | ND | ND | ND | 21 | Yes | 8 | |
| 12 | Villella | Int J Gynecol Pathol | 17413982 | 2007 | 48 | 1970-2005 | 136 (1-436) | ND | ND | ND | ND | 13% | Yes | ND | |
| 13 | Lee | Int J Gynecol Cancer | 17868338 | 2008 | 35 | 1987-2005 | 177 (8-212) | ND | ND | ND | ND | 23% | Yes | 8% | |
| 14 | Pectasides | Anticancer Res | 18505090 | 2008 | 34 | 1983-2007 | 34 | ND | ND | 89% | 89% | 26% | Yes | ND | |
| 15 | Ranganath | Int J Gynecol Cancer | 18081789 | 2008 | 31 | 1995-2005 | ND | ND | ND | ND | ND | 31% | Yes | ND | |
| 16 | Li | Saudi Med J | 19198715 | 2009 | 46 | 1995-2005 | range 26-176 | ND | ND | ND | ND | 19 | Yes | 4% | |
| 17 | Kondli-Pafiti | Eur J Gynecol Oncol | 20349790 | 2010 | 15 | 1996-2005 | 36 (2-26) | ND | ND | ND | ND | 20 | Yes | ND | |
| 18 | D'Angelo | Mod Pathol | 21623383 | 2011 | 34 | 1984-2009 | 108 (24-312) | ND | ND | ND | ND | 41 | Yes | ND | |
| 19 | Nirmala | J Obstet Gynecol India | 23730038 | 2012 | 37 | 1990-2006 | 60 | ND | ND | 93% | ND | 14 | Yes | 24% | 17 (70%) FOXL2 mutation positive 18 (35%) FOXL2 mutation positive 3 patients included without histological verification Only stage I patients 256 FOXL2 mutation positive AGCTs |
| 20 | Mangili | Br J Cancer | 23756859 | 2013 | 97 | 1965-2008 | 88 (6-498) | 97 | 95% | ND | ND | 34 | Yesd | ND | |
| 21 | Rosario | Gynecol Oncol | 24007948 | 2013 | 57 | 1955-2011 | 112 (2-497) | ND | ND | ND | ND | 44 | Yes (only in 37) | ND | |
| 22 | Haroon | J Ovarian Res | 24304499 | 2013 | 211 | 1992-2012 | ND | ND | ND | ND | ND | 6 | Yes | ND | |
| 23 | Byk | Int J Gynecol Cancer | 25347095 | 2015 | 187 | 1956-2012 | 164 (1-608) | 97 | 92 | 94 | 87 | 29 | Yes | 17 | |
| 24 | Ugianskiene | Eur J Gynecol Oncol | 25556264 | 2014 | 37 | 1985-2010 | ND | ND | ND | ND | ND | 6 | Yes | 3% | |
| 25 | Ud Din | Annals of Diagn Pathol | 24630126 | 2014 | 156 | 1992-2012 | ND | ND | ND | ND | ND | 5 | Yes | ND | |
| 26 | Shim | Anticancer Res | 24511046 | 2014 | 91 | 1989-2011 | 58 (3-254)c | ND | ND | ND | ND | 17 | Yes | ND | |
| 27 | Wilson | Gynecol Oncol | 26003143 | 2015 | 160 | 1955-2012 | 84 (1-528) | 99 | 96 | 99 | 92 | 32 | Yes (only in 57) | ND | |
| 28 | Karalok | Int J Gynecol Cancer | 26825833 | 2016 | 158 | 1988-2013 | 97 (1-296) | 96 | 88 | ND | ND | 13 | Yes | ND | 17 (70%) FOXL2 mutation positive 18 (35%) FOXL2 mutation positive 3 patients included without histological verification Only stage I patients 256 FOXL2 mutation positive AGCTs |
| 29 | McConechy | J Natl Canc Inst | 27297428 | 2016 | 256 | 1956-2013 | 132f | 97 | 92 | 93 | 84 | 28e | Yes | 19 | |

A pub med search with "granulosa cell tumor prognosis" was performed in 5/2016 and articles in english were evaluated based on the title and abstract. Studies in which the histology of the cases had been reviewed and that reported the survival (OS or DSS) or recurrence of patients with only adult ovarian granulosa cell tumors were included. Abbreviations: #; number, pub; publication, mo; months, DSS; disease-specific survival, OS; overall survival, dg; diagnosis, ND; not defined, pt; patients, yr; year.

^aEnd time estimated.

^bReported as recurrent and metastatic combined.

^cMean (range).

^dHistological review in the treating hospital, not for the study.

^eRelapse-rate in the Finnish, population-based cohort of 165 AGCTs.

^fReported as reverse Kaplan-Meier.

Accurate diagnosis

AGCTs are relatively uncommon and can show histomorphological patterns similar to a variety of other unrelated tumors, therefore an unequivocal diagnosis of AGCT can be challenging. Consequently, in historical series false positive diagnosis rates of up to 36% have been recorded (4,12). A single somatic missense mutation (C134W) in the gene encoding for transcription factor FOXL2 has been found to be present in ~95% of AGCTs, making it a pathognomonic defining feature (24), and this finding has been verified in multiple independent cohorts (11,25–29). The mutation is specific to AGCT, and is not present in any other tumors including juvenile GCTs (30,31). Thus, the FOXL2 mutation has been shown to be essential in the differential diagnosis of AGCTs (32,33). In conjunction with expert pathological morphologic assessment, FOXL2 mutation testing, and the appropriate immunohistochemical markers is strongly recommended for current clinical pathological diagnoses (11,32,34). As direct Sanger sequencing for the FOXL2 mutation, especially from formalin the fixed paraffin-embedded tissue can often result in false negative results (32), the mutational analysis is recommended to be performed using an allelic discrimination assay or other sensitive methods (11). An accurate diagnosis is crucial since misdiagnosis can have profound effects on patient prognosis; the majority of misdiagnosed cases have been shown to be more aggressive tumors with significantly worse outcomes (11). Conversely, molecularly defined AGCTs present with a consistently indolent course with slow progression. Incorporating FOXL2 mutation testing into routine pathological assessment will aid in moving towards a universal and reproducible correct diagnoses, and create uncontaminated cohorts for clinical trials.

Due to recent technical developments, the specific FOXL2 mutation offers an intriguing opportunity for non-invasive diagnostics from cell-free circulating tumor DNA (ctDNA) (35). The advances in digital droplet PCR technology has allowed for the development of a sensitive and specific technique to identify low-frequency FOXL2 ctDNA mutations in a high background of wild-type DNA (36). According to this recent proof of principle study, the FOXL2 mutation was found in the ctDNA from 35% of patients with primary AGCT, and 19% of patients with relapsed disease. Consistent with previous findings (37), the mutation was more likely found from the plasma of patients with larger tumors (36). The question arises whether ctDNA FOXL2 mutation positivity at primary diagnosis or during follow-up can predict tumor recurrence,

similar to findings in patients with early-stage breast cancer (37). However, the clinical utility of ctDNA FOXL2 mutation in AGCT patients will need to be further developed and validated in future clinical trials.

Pathogenesis

Molecular pathogenesis

The transcription factor FOXL2 plays a crucial role in regulating follicular development in the normal ovary (38), and it is crucial for granulosa cell differentiation (39). In AGCTs, the mechanism how the FOXL2 mutation causes tumor formation remains an area of active investigation. At the molecular level, the C134W mutation is not linked to alterations in the protein structure (40), but instead it causes a change in the posttranslational modification (ubiquitination) leading to impaired interactions of FOXL2 with other transcription factors (41). The current evidence suggests that a key event in AGCT pathogenesis is a failure of the mutant FOXL2 to form specific protein–protein interactions leading to subtle changes in the transcription of target genes (42). This creates a transcriptomics profile portraying the typical hallmarks of cancer (43). The impact of the FOXL2 mutation in AGCT pathogenesis is depicted in Figure 1.

Interplay of transcription factors

A key result of the FOXL2 mutation seems to be in the dysregulation of cell cycle and apoptosis. Wild-type FOXL2 negatively regulates cell-cycle progression (44) and promotes apoptosis (45). In contrast, the FOXL2 C134W mutant upregulates genes involved in cell-cycle progression and downregulates genes involved in apoptosis (43,45,46). Mutant FOXL2 has been linked to altered interactions with the SMAD transcription factors of the TGF- β /BMP signaling pathway (40,47), which are essential intracellular mediators in normal granulosa cells. A key effect of FOXL2 appears to be mediated through its interaction with SMAD3 (48,49). In normal granulosa cells, SMAD3 mediates activin A and transforming growth factor- β (TGF- β) signals regulating the expression of cyclin D2 and gonadal genes such as inhibin (50). In AGCTs, SMAD3 has been shown to differentially regulate a gonadotrophin releasing hormone activating promoter together with mutant FOXL2 as compared to wild-type FOXL2 (40). Furthermore, mutant FOXL2 has been shown to inhibit the induction of anti-proliferative follistatin, leading to increased cell proliferation and tumor formation (51).

In addition to SMAD3, FOXL2 interacts with multiple transcription partners in AGCTs. GATA4 is a zinc finger

transcription factor that plays a crucial role in ovarian follicular development granulosa cells being the major site of GATA4 expression in the ovary (52). In granulosa cells, follicle stimulating hormone (FSH) and TGF- β upregulate the expression of GATA4 (53), and GATA4 subsequently acts to moderate many factors crucial for granulosa cell proliferation and function (53), including AMH (54), aromatase (55), and α -inhibin (54). The majority of AGCTs express GATA4 at levels comparable to normal preovulatory granulosa cells (52), and high GATA4 expression in these tumors predicts both increased risk of recurrence and shorter disease specific survival (22). Further, GATA4 protein expression correlates with the expressions of the intrinsic apoptotic pathway inhibitor Bcl2, and proproliferative cyclin D2 (56), and overexpression of GATA4 protects AGCT cells from apoptosis (57). GATA4 has also been shown to physically interact with SMAD3 and FOXL2 to modulate gene expression, cell viability, and apoptosis in AGCTs (58). Taken together, these data suggest that GATA4 acts as an anti-apoptotic factor promoting tumor growth in AGCTs. Although FOXL2 and GATA4 play pivotal roles in AGCT tumorigenesis, they are difficult to target when developing new treatment strategies for advanced AGCT. Therefore, future therapeutic agents may need to be targeted at the downstream effects of these transcription factors, most importantly factors related to apoptosis, proliferation and hormonal regulation.

Hormonal factors

AGCTs are derived from the rapidly dividing granulosa cells of small preantral follicles, and express the receptors for several hormonal regulators (59). Wild-type FOXL2 regulates the expression of multiple hormonal factors such as SF1, CYP19A1, HSD17B1, ESR1, ALK6 (BMPRII), SOX9, and StAR (60,61). Wild-type FOXL2 causes the repression of StAR and an increase in CYP19A1 maintaining the female phenotype in granulosa cells (39). In granulosa cells, follicle-stimulating hormone (FSH) is an integral regulator of proliferation and hormonal function. FSH binds to its transmembrane receptor, activates transcription via cAMP-mediated pathways resulting in increased expression of, e.g. CYP19A1 (aromatase) and cyclin D2, and promoting cell proliferation. AGCTs are known to express functional FSH receptors activating FSH signaling (62). At diagnosis, AGCT patients typically present with low-circulating FSH levels due to inhibitory feed-back mechanisms of tumor-produced estradiol and inhibins. The pathogenetic role of FSH in AGCTs remains inconclusive, and several studies have failed to identify

genetic alterations in FSH receptor, or other G-protein coupled receptors (59,62). In addition to FSH, FOXL2 regulates aromatase expression, and mutant FOXL2 has been shown to directly activate the aromatase promoter (63). AGCT cells have abundant aromatase activity (64), and consequently AGCTs produce estrogens (65). AGCTs also express high levels of estrogen receptors; nuclear estrogen receptor (ER) α expression has been reported in a minority (20%) of AGCTs, whereas virtually all AGCTs are ER β positive (66). In addition, AGCTs have been reported to express a newly characterized, membrane-bound G-protein linked estrogen receptor (GPER1 or GPR30) (67). The para/autocrine actions of tumor-secreted estradiol are unknown, and evidence supporting the assumption that endogenous estradiol promotes tumor growth is lacking. By contrast, it has been shown that estradiol binding to nuclear estrogen receptors (ER α or ER β) does not activate transcription in AGCT cells due to repression by the NF κ B pathway via SMAD3 (68,69). In addition, recent evidence suggests that estradiol may in fact decrease metastasis and invasion of AGCT cells via activation of GPER1 (67). The effects of tumor-produced and exogenous estradiol, such as hormone replacement therapy, need to be further explored. This is also vital in order to interrogate the mechanism of action of the currently applicable hormonal treatments, such as aromatase inhibitors. A recent single-institute retrospective study reported only modest responses with hormone therapy (objective response rate 18%), although a significant proportion (60%) of the patients remained with stable disease (70). Future studies will hopefully shed more light into whether the hormonal pathways can also be exploited to prevent relapse in high-risk patients similar to other hormone-dependent cancers.

TGF- β family members

Anti-müllerian hormone (AMH), also referred to as Müllerian inhibiting substance, belongs to the TGF- β /bone morphogenic protein family of signaling molecules. AMH is a key regulator of follicular development in the ovary (71). In granulosa cells, AMH expression is regulated by steroidogenic factor-1, GATA4 (72), and FSH (73), and the granulosa cell-produced AMH further regulates follicular development in the ovary (71). AMH exerts its effects by binding to a heterodimeric cell surface receptor complex consisting of type I and type II (AMHRII) receptors, that activate downstream SMAD 1, 5, and 8. In the adult female, AMHRII is expressed in granulosa cells and at low levels in ovarian stroma and endometrium (74). In gynecological

cancers, AMRII is highly expressed in cancers of the ovary, endometrium (74). AGCTs are known to express AMH, and AMH has been shown to act as a sensitive and specific circulating tumor marker for AGCT (75). Interestingly, several mouse models suggest that imbalances in the TGF- β /bone morphogenic pathway, and specifically the overactivity of TGF- β -type signaling and SMAD2/3 contributes to GCT formation (76). Further, recombinant human AMH was shown to activate SMAD1/5 signaling and induce apoptosis in AGCT cells (77), indicating that AMH pathway acts as a growth inhibitor also in AGCTs. AMH targeting agents may thus present as an interesting therapeutic option for AGCTs. Moreover, receptors that are highly and specifically expressed in cancers, such as AMHRII, present as rational targets for the development of novel therapies (78).

Tumor angiogenesis

Tumor growth relies on mechanisms of angiogenesis, the growth of new blood vessels from pre-existing vasculature in order to supply oxygen and nutrients. This angiogenic process in tumors is mainly driven by Vascular Endothelial Growth Factor-A (VEGF). In growing tumors, hypoxia is the main stimulator of VEGF expression through hypoxia-inducible factor 1 α (HIF-1 α), but also many cytokines and growth factors, such as TGF- α and TGF- β stimulate VEGF expression (79). VEGF is expressed in the majority of solid tumors as well as in some hematological malignancies, and its expression correlates with disease progression and survival (79). AGCTs are typically highly vascularized and express VEGF and its receptors (80). VEGF signaling seems to be required for the survival of AGCT cells *in vitro* (80) and tumor progression *in vivo* (81), suggesting that VEGF contributes to angiogenesis and tumor progression also in AGCTs.

Treatment

During the last decade, our understanding of the molecular pathogenesis of AGCTs has significantly improved, whereas the developments of chemotherapeutic regimens and especially targeted therapies have remained modest. Thus, optimal primary surgery still has kept its position as the most determining factor in the treatment of both primary and relapsed AGCTs.

Surgery

In the treatment of primary AGCT, complete surgical removal of the tumor, uterus, ovaries and fallopian

tubes, complemented with staging procedures (peritoneal washings, biopsies, and infracolic omentectomy) form the golden standard (82). Pelvic and para-aortic lymphadenectomy (i.e. surgical removal of lymph nodes) are generally not recommended (82), and only bulky or suspicious nodes should be removed. Surgery can be performed in either laparotomy or laparoscopy (33% of primary operations), while the laparoscopic approach has been reported safe and associates with less morbidity (83). In patients presenting with a local disease (stage Ia) and wishing to preserve their fertility, a conservative surgery sparing the normal contralateral ovary and uterus can be performed. In these cases, however, a careful staging procedure coupled with endometrial sampling should be carried out to exclude metastatic disease and/or concurrent endometrial pathology. It is noteworthy, that there is no consensus of whether radical surgery should be performed when these patients have completed their childbearing or when they reach menopause.

The relapsed disease is often multifocal, and complicated by the fact that there is no standard surgical approach or treatment protocol. The most common site of relapse is the pelvis, but abdominal and peritoneal disease, as well as retroperitoneal metastases can occur (5,83,84). Similar to primary disease, the treatment of relapsed disease should aim for optimal surgical debulking whenever possible (5,82,84). This is crucial since the presence of postoperative residual tumor has been shown to be an important prognostic factor for both subsequent tumor relapse, and survival (8,13). Further, patients with recurrent disease are likely to benefit even from repeated surgical approaches if optimal debulking can be achieved (5). And indeed, according to two retrospective reports, an optimal debulking with no macroscopic residual tumor can be achieved in the majority of the patients in secondary surgery (83,84). However, multivisceral surgical procedures may be needed to achieve optimal debulking, which associate with a significantly increased risk of postoperative complications. However, a prolonged disease-free survival was reported in a small patient series regardless of the additional risks associated with repeated and extensive surgical procedures (85).

Chemotherapy

Surgery forms the cornerstone of treatment in most AGCTs that are diagnosed at an early stage, and no medical therapies are usually considered. Advanced and/or inoperable chemotherapy is offered, although its efficacy and prognostic significance largely remain unsure. The role of adjuvant chemotherapy in AGCTs

is also obscure; reasonably high response rates have been reported (86,87), however, adjuvant chemotherapy does not seem to significantly affect patient outcomes (8). Traditionally, platinum-based combination therapies have been utilized as the primary therapeutic option (88,89). Response rates for the most common combination of bleomycin, etoposide and cisplatin vary from 37% to 83% in older studies (88,90), but in the most recent series the responses are only moderate, reaching 22–35% (9,89). It must be noted, however, that the current evidence is based on mostly retrospective studies on non-validated AGCT cohorts, presenting as a potential confounder when evaluating these responses. Combination chemotherapy with paclitaxel and carboplatin has also been used, providing with the same efficacy albeit less toxicity compared with bleomycin, etoposide and cisplatin (90). Interestingly, The Gynecologic Oncology Group is currently running a randomized trial comparing these two combination treatments, hopefully providing a clarification to the choice of optimal chemotherapeutic regimen.

Hormonal and targeted treatments

AGCTs are known to express steroid hormone receptors and produce estradiol. Therefore, hormonal treatments have been empirically utilized in AGCTs, mostly as a last resort in patients with non-operable AGCTs. Hormonal therapies have also been considered if the patient has not tolerated or the tumor has not responded to conventional chemotherapy. The treatment modalities have included progestins, gonadotrophin releasing hormone agonist, selective estrogen receptor modulators, and aromatase inhibition. In a systematic review including 19 studies describing the response to hormonal therapy, the pooled objective response rate was as high as 71% (91). However, in a retrospective analysis of 22 patients from a single institute, the objective response rate was unexpectedly low (18%) (70). Similarly, Wilson et al. reported a response rate of 14% to aromatase inhibitors in patients with relapsed stage I AGCTs (9). It is noteworthy, that no randomized trials have been performed regarding hormonal treatments, and the current literature consists only relatively small retrospective series and case reports. In addition, none of these studies have been performed in FOXL2 molecularly defined cohorts, and there is potential bias from patient selection and response evaluation for the benefit of these treatments. Thus, the true efficacy of hormonal therapy in AGCTs remains unknown. Further, the biological principles and mechanisms of action of

hormonal treatments in AGCTs are unclear (see above). After the hormonal pathogenesis is clarified in more detail, and there is supportive evidence from a randomized trial, hormonal therapy may be an option in the treatment of AGCTs.

The only targeted therapy with proven efficacy in advanced ovarian cancer is angiogenesis inhibition, most importantly with humanized monoclonal VEGF antibody bevacizumab (92). In AGCTs, bevacizumab was considered active in a phase II clinical trial on advanced AGCTs (93). Thus, bevacizumab may be a viable option in advanced AGCTs.

Follow-up and timing of treatment

Follow-up of AGCT patients consists of standard gynecological examinations with ultrasound and blood samples for at least 3–5 years (82,94). The roles of gynecological exam and transvaginal ultrasound in clinical follow-up are unclear as their sensitivity to detect relapses outside the pelvis are limited. Thus, serum markers are commonly utilized as a part of the standard follow-up scheme. Serum inhibin B has the strongest evidence as a tumor marker for AGCTs (95). Granulosa cells of developing follicles produce inhibin B and its serum levels are high in the early follicular phase (96). After menopause, circulating inhibin B concentrations are undetectable. In AGCT patients, inhibin B is superior to inhibin A, with reported sensitivities between 88–100% for inhibin B, and 67–77% for inhibin A, respectively (97). AMH has also been validated as a marker for AGCT, and both AMH and inhibin B are equally sensitive (92 and 93%) and specific (82 and 83%) in this disease (75). In addition, both markers are also elevated in relapsed disease and their levels positively correlate with disease burden (75). The combination of AMH and inhibin B seems to be superior to inhibin B alone in detecting macroscopic disease. In premenopausal patients, there are no established cut-off levels for AMH or inhibin B, and new studies are needed to establish the reference values for AMH and inhibin B. Currently, the levels should be evaluated individually, and patients with rising AMH vaifact that functional granulosa cells are the only source of AMH and inhibin B. It is thus recommended that both markers should be measured at diagnosis, and subsequently one positive marker, either AMH or inhibin B, may be monitored during follow-up (75).

AMH and inhibin B levels have been reported to rise several months or even years before the onset of clinical symptoms of the relapse, the lead-times have been reported 0.9–2.8 years for inhibin B, and 3.4 years for AMH (75,97). The clinical significance of the

Table 2. Challenges and suggested solutions in the management of AGCT patients.

| AGCT characteristic | Clinical challenge | Suggested solution and objects for future studies |
|--|---|---|
| Importance of optimal primary surgical treatment on prognosis | Surprise AGCT diagnosis or tumor rupture at operation leading to higher stage, typically Ic, and increased risk of relapse. | Accurate preoperative diagnostics with e.g. circulating tumor markers (AMH, inhibin B), and the referral of AGCT patients to a gynecological oncologist for primary treatment. |
| Significant variation in outcomes, unpredictable clinical course | Unequivocal histological diagnosis, and the lack of prognostic indicators to identify patients at risk of relapse | Diagnosis verification with <i>FOXL2</i> 402C->G mutation testing, preferably with a sensitive method such as allelic discrimination assay. Identification of prognostic markers among molecularly validated AGCTs. |
| Long latency to relapse | How, and how long to follow-up the patients | Use of accurate serum markers (AMH, inhibinB), identification of "high risk" patients with e.g. ctDNA |
| Relapse in 30% of the early stage patients | Which patients are in need of prolonged follow-up | Identification of patients at high risk of relapse that most likely benefit from adjuvant therapy and possibly maintenance therapy to prevent relapse. |
| Increased (50%) mortality to relapsed AGCT | How to optimally treat relapsed AGCT, what chemotherapeutics are effective. | New studies on chemotherapy and targeted treatments, as well as hormonal therapy. |

early marker rise in regards to patient survival and morbidity can only be speculated upon. To date, there is no evidence supporting the treatment of asymptomatic ovarian cancer patients (98). However, early detection of a relapse by close monitoring with serum markers may result into a more optimal surgical management of the relapse (99).

Treatment challenges and future perspectives

The key challenges and suggested solutions in the management of AGCT patients are summarized in Table 2. In support of recent evidence, accurate diagnostics is the cornerstone in the treatment of AGCT patients, and expert pathological review in conjunction with *FOXL2* mutation testing should become the standard of care for patients with AGCT.

The surgical treatment of AGCT should aim for optimal cytoreduction, coupled with complete staging, and the centralization of treatment of these patients is essential to ensure the quality and resources of the treatment. The prognostic difference between stage Ia and Ic patients is clinically relevant (17), and special attention should be paid on the surgical management of these patients. In stage Ia patients, rigorous efforts should be concentrated at preventing tumor rupture and dissemination of the tumor cells onto the abdominal cavity during operation. Upon laparoscopic approach, this requires a trained endoscopic surgeon, and the use of special instruments to safely remove the tumor. This underlines the importance of the preoperative evaluation, and the referral of these patients to a gynecological oncologist for primary care.

Further, a major clinical challenge is to identify patients at risk of recurrence. In addition to tumor stage, the current literature offers no consistent prognostic factors. Therefore, further studies in validated

cohorts are needed to identify AGCT patients at increased risk of relapse, and to find out whether they would benefit from adjuvant treatments or maintenance therapy to prevent recurrence

A demanding clinical challenge also arises from the treatment of relapsed or advanced molecularly defined AGCTs. In these cases, platinum-based adjuvant chemotherapy is commonly utilized. However, it is known that platinum-based therapies most efficiently target rapidly dividing cells with DNA repair defects. Further, the rationale of using platinum in AGCTs is based on small, mostly retrospective series, and more importantly from cohorts with no diagnostic validation (89). Recent studies have shown that the patients with the most aggressive AGCTs are more likely to have a different tumor type and are not AGCTs (11), causing potential bias when evaluating the treatment responses from historical cohorts. Notably, AGCTs seem to retain the pathognomonic *FOXL2* mutation, and their original gene expression profile and chromosomal architecture even after multiple relapses. The clinical picture of AGCT with slow growth, indolent prognosis supports the use of conservative approach to adjuvant therapy with conventional chemotherapeutics so as to avoid toxicity. Considering the pathogenesis and stable karyotype of *FOXL2* molecularly defined AGCTs, new approaches are needed to find new, effective treatment options for patients with relapsed and inoperable AGCT.

The relative rarity of the tumor and its prolonged disease course make studies on new drugs and combinations in prospective clinical trials difficult and time-consuming. Large international clinical trials with molecularly defined AGCT cohorts are needed to validate new treatment strategies for patients with high-risk early-stage and advanced AGCTs. The establishment of new effective treatments should also rely




Figure 1. AGCT pathogenesis. The central pathogenic FOXL2 mutation 402C > G (C134W) alters gene expression in AGCTs leading to increased proliferation, decreased apoptosis, and characteristic hormonal alterations. In addition, there are multiple intrinsic signaling routes that inhibit the growth of AGCTs. Red arrows up indicate increased expression related to mutant FOXL2, and blue arrows down indicate decreased expression, respectively. Solid arrows indicate activating signal and dashed arrows indicate inhibiting signal. Transcription factors FOXL2 (C134W), GATA4 and SMAD3 co-operatively regulate gene expression in AGCTs. Increased activity of SMAD3 of the TGF- β pathway leads to proliferation and transcriptional changes, while decreased expression of follistatin (FST) increases the pro-tumorigenic Activin signaling, as the expression of its receptor (ACVR) is simultaneously increased. The signal mediators of the growth-inhibitory AMH/BMP- type pathway are decreased in AGCTs. Due to FOXL2 mutation and FSH signaling, the expression of pro-proliferative factor Cyclin D2 is increased in AGCTs contributing to increased proliferation. Apoptosis is decreased in AGCTs both due to decreased expression of pro-apoptotic factors such as Fas and TNFR1, and increased expression of anti-apoptotic factors such as Bcl2. The hormonal changes associated with AGCTs include expression of aromatase enzyme (CYP19A1) leading to estradiol (E2) production. ER β transcriptional activation is inhibited by increased expression of NFK β and c-Jun, whereas GPER1 activation by E2 seems to decrease migration and invasion in AGCTs via p-ERK1/2. Circulating E2, and inhibin (α chain in the tissue, A/B in the circulation) inhibit GnRH release from the hypothalamus, leading to decreased release of FSH from the pituitary. The hormonal treatments utilized in AGCT include aromatase inhibitor (AI), as well as GnRH analog/antagonists (GnRHi). Abbreviations: AI: Aromatase inhibitor; AMH: Anti-Müllerian hormone; BMP: Bone Morphogenetic Factor; E2: Estradiol; FSH: Follicle stimulating hormone; FST: Follistatin; GnRH: Gonadotrophin Releasing Hormone; NFK β : Nuclear Factor kappa- β ; p-ERK1/2: phosphorylated Extracellular Signal-Regulated Kinases 1/2; TGF- β : Transforming Growth Factor- β ; TT: testosterone.

on the deeper understanding of the pathogenesis of AGCTs.

Acknowledgements

We wish to thank Mrs Helena Schmidt for graphical assistance.

Disclosure statement

David Huntsman is founder and shareholder of Contextual genomics Inc. The other authors report no conflicts of interest.

Funding

Sigrid Jusélius Foundation, Helsinki University Hospital Research Funds, The Academy of Finland.

References

1. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. *Endocr Rev.* 2012;33: 109–44.
2. Bryk S, Pukkala E, Martinsen JI, Unkila-Kallio L, Tryggvadottir L, Sparen P, et al. Incidence and occupational variation of ovarian granulosa cell tumours in

- Finland, Iceland, Norway and Sweden during 1953–2012: a longitudinal cohort study. *BJOG*. 2017;124:143–49.
3. Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. *Am J Surg Pathol*. 1984;8:575–96.
4. Bryk S, Farkkila A, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience. *Int J Gynecol Cancer*. 2015;25:33–41.
5. Mangili G, Ottolina J, Gadducci A, Giorda G, Breda E, Savarese A, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. *Br J Cancer*. 2013;109:29–34.
6. Kim JA, Chun YK, Moon MH, Lee YH, Cho HC, Lee MS, et al. High-resolution sonographic findings of ovarian granulosa cell tumors: correlation with pathologic findings. *J Ultrasound Med*. 2010;29:187–93.
7. van Meurs HS, Bleeker MC, van der Velden J, Overbeek LI, Kenter GG, Buist MR. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. *Int J Gynecol Cancer*. 2013;23:1417–22.
8. Sun HD, Lin H, Jao MS, Wang KL, Liou WS, Hung YC, et al. A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. *Gynecol Oncol*. 2012;124:244–9.
9. Wilson MK, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al. Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up. *Gynecol Oncol*. 2015;138:285–91.
10. Prat J. Oncology FCoG. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. *J Gynecol Oncol*. 2015;26:87–9.
11. McConechy MK, Farkkila A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, et al. Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype. *J Natl Cancer Inst*. 2016;108:djw134.
12. Cronje HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the Emil Novak ovarian tumor registry. *Am J Obstet Gynecol*. 1999;180:323–7.
13. Lee IH, Choi CH, Hong DG, Song JY, Kim YJ, Kim KT, et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. *J Gynecol Oncol*. 2011;22:188–95.
14. East N, Alobaid A, Goffin F, Ouallouche K, Gauthier P. Granulosa cell tumour: a recurrence 40 years after initial diagnosis. *J Obstet Gynaecol Can*. 2005;27:363–4.
15. Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. *Clin Cancer Res*. 2013;19:6389–97.
16. Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP. Characteristics of recurrence in adult-type granulosa cell tumor. *Int J Gynecol Cancer*. 2008;18:642–7.
17. Bryk S, Färkkilä A, Butzow R, Leminen A, Tapper J, Heikinheimo M, et al. Characteristics and outcomes of recurrence in the molecularly defined adult-type ovarian granulosa cell tumor. *Gynecol Oncol*. 2016;143:571–77.
18. Bjorkholm E, Silfversward C. Prognostic factors in granulosa-cell tumors. *Gynecol Oncol*. 1981;11:261–74.
19. Auranen A, Sundstrom J, Ijas J, Grenman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. *Int J Gynecol Cancer*. 2007;17:1011–8.
20. Nosov V, Silva I, Tavassoli F, Adamyan L, Farias-Eisner R, Schwartz PE. Predictors of recurrence of ovarian granulosa cell tumors. *Int J Gynecol Cancer*. 2009;19:628–33.
21. Miller BE, Barron BA, Dockter ME, Delmore JE, Silva EG, Gershenson DM. Parameters of differentiation and proliferation in adult granulosa cell tumors of the ovary. *Cancer Detect Prev*. 2001;25:48–54.
22. Farkkila A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor—a long-term follow-up study. *Cancer Med*. 2014;3:526–36.
23. Miller K, McCluggage WG. Prognostic factors in ovarian adult granulosa cell tumour. *J Clin Pathol*. 2008;61:881–4.
24. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. *N Engl J Med*. 2009;360:2719–29.
25. Kim T, Sung CO, Song SY, Bae DS, Choi YL. FOXL2 mutation in granulosa-cell tumours of the ovary. *Histopathology*. 2010;56:408–10.
26. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. *Mod Pathol*. 2010;23:1477–85.
27. Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. *Am J Surg Pathol*. 2011;35:484–94.
28. Gershon R, Aviel-Ronen S, Korach J, Daniel-Carmi V, Avivi C, Bar-Ilan D, et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. *Gynecol Oncol*. 2011;122:580–4.
29. Schrader KA, Gorbacheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, et al. The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. *PLoS One*. 2009;4:e7988.
30. Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. *J Pathol*. 2010;221:147–52.
31. D'Angelo E, Mozos A, Nakayama D, Espinosa I, Catusus L, Munoz J, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. *Mod Pathol*. 2011;24:1360–7.
32. Kommos S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. *Mod Pathol*. 2013;26:860–7.
33. McCluggage WG, Singh N, Kommos S, Huntsman DG, Gilks CB. Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor. *Am J Surg Pathol*. 2013;37:1450–5.

34. Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, et al. Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. *Gynecol Oncol*. 2014;132:181–7.
35. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6:224ra24.
36. Farkkila A, McConechy MK, Yang W, Talhouk A, Ying NG, Lum A, et al. FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor. *J Mol Diagn*. 2017;19:126–36.
37. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. *EMBO Mol Med*. 2015;7:1034–47.
38. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, et al. The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. *Development*. 2004;131:933–42.
39. Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. *Cell*. 2009;139:1130–42.
40. Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, et al. Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G). *PLoS One*. 2010;5:e8789.
41. Kim JH, Kim YH, Kim HM, Park HO, Ha NC, Kim TH, et al. FOXL2 posttranslational modifications mediated by GSK3 β determine the growth of granulosa cell tumours. *Nat Commun*. 2014;5:2936.
42. L'Hote D, Georges A, Todeschini AL, Kim JH, Benayoun BA, Bae J, et al. Discovery of novel protein partners of the transcription factor FOXL2 provides insights into its physiopathological roles. *Hum Mol Genet*. 2012;21:3264–74.
43. Benayoun BA, Anttonen M, L'Hote D, Bailly-Bechet M, Andersson N, Heikinheimo M, et al. Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation. *Oncogene*. 2013;32:2739–46.
44. Benayoun BA, Georges AB, L'Hote D, Andersson N, Dipietromaria A, Todeschini AL, et al. Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase. *Hum Mol Genet*. 2011;20:1673–86.
45. Kim JH, Yoon S, Park M, Park HO, Ko JJ, Lee K, et al. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W). *Oncogene*. 2011;30:1653–63.
46. Rosario R, Araki H, Print CG, Shelling AN. The transcriptional targets of mutant FOXL2 in granulosa cell tumours. *PLoS One*. 2012;7:e46270.
47. Kobel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. *Cancer Res*. 2009;69:9160–2.
48. Tran S, Lamba P, Wang Y, Bernard DJ. SMADs and FOXL2 synergistically regulate murine FSHbeta transcription via a conserved proximal promoter element. *Mol Endocrinol*. 2011;25:1170–83.
49. Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, Bilezikjian LM. FoxL2 and Smad3 coordinately regulate follistatin gene transcription. *J Biol Chem*. 2009;284:7631–45.
50. Park Y, Maizels ET, Feiger ZJ, Alam H, Peters CA, Woodruff TK, et al. Induction of cyclin D2 in rat granulosa cells requires FSH-dependent relief from FOXO1 repression coupled with positive signals from Smad. *J Biol Chem*. 2005;280:9135–48.
51. McTavish KJ, Nonis D, Hoang YD, Shimasaki S. Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells. *Mol Cell Endocrinol*. 2013;372:57–64.
52. Laitinen MP, Anttonen M, Ketola I, Wilson DB, Ritvos O, Butzow R, et al. Transcription factors GATA-4 and GATA-6 and a GATA family cofactor, FOG-2, are expressed in human ovary and sex cord-derived ovarian tumors. *J Clin Endocrinol Metab*. 2000;85:3476–83.
53. Kyrölähti A, Vetter M, Euler R, Bielinska M, Jay PY, Anttonen M, et al. GATA4 deficiency impairs ovarian function in adult mice. *Biol Reprod*. 2011;84:1033–44.
54. Anttonen M, Parviainen H, Kyrölähti A, Bielinska M, Wilson DB, Ritvos O, et al. GATA-4 is a granulosa cell factor employed in inhibin- α activation by the TGF- β pathway. *J Mol Endocrinol*. 2006;36:557–68.
55. Tremblay JJ, Viger RS. GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements. *Endocrinology*. 2001;142:977–86.
56. Kyrölähti A, Ramo M, Tamminen M, Unkila-Kallio L, Butzow R, Leminen A, et al. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. *Endocrinology*. 2008;149:5635–42.
57. Kyrölähti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefstrom J, et al. GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. *Endocr Relat Cancer*. 2010;17:709–17.
58. Anttonen M, Pihlajoki M, Andersson N, Georges A, L'Hote D, Vattulainen S, et al. FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells. *PLoS One*. 2014;9:e85545.
59. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. *Trends Endocrinol Metab*. 2004;15:122–8.
60. Park M, Shin E, Won M, Kim JH, Go H, Kim HL, et al. FOXL2 interacts with steroidogenic factor-1 (SF-1) and represses SF-1-induced CYP17 transcription in granulosa cells. *Mol Endocrinol*. 2010;24:1024–36.
61. Caburet S, Georges A, L'Hote D, Todeschini AL, Benayoun BA, Veitia RA. The transcription factor FOXL2: at the crossroads of ovarian physiology and pathology. *Mol Cell Endocrinol*. 2012;356:55–64.

62. Fuller PJ, Verity K, Shen Y, Mamers P, Jobling T, Burger HG. No evidence of a role for mutations or polymorphisms of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. *J Clin Endocrinol Metab*. 1998;83:274–9.
63. Fleming NI, Knowler KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD. Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. *PLoS One*. 2010;5:e14389.
64. Kato N, Uchigasaki S, Fukase M, Kurose A. Expression of P450 aromatase in granulosa cell tumors and sertoli-stromal cell tumors of the ovary: which cells are responsible for estrogenesis? *Int J Gynecol Pathol*. 2016;35:41–7.
65. Amsterdam A, Selvaraj N. Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. *Endocr Rev*. 1997;18:435–61.
66. Hutton SM, Webster LR, Nielsen S, Leung Y, Stewart CJ. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary. *Pathology*. 2012;44:611–6.
67. Francois CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, et al. 17beta-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. *Carcinogenesis*. 2015;36:564–73.
68. Bilandzic M, Chu S, Wang Y, Tan HL, Fuller PJ, Findlay JK, et al. Betaglycan alters NFkappaB-TGFbeta2 cross talk to reduce survival of human granulosa tumor cells. *Mol Endocrinol*. 2013;27:466–79.
69. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ. Transrepression of estrogen receptor beta signaling by nuclear factor-kappaB in ovarian granulosa cells. *Mol Endocrinol*. 2004;18:1919–28.
70. van Meurs HS, van der Velden J, Buist MR, van Driel WJ, Kenter GG, van Lonkhuizen LR. Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary. *Acta Obstet Gynecol Scand*. 2015;94:1269–75.
71. Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. *Reproduction*. 2006;131:1–9.
72. Anttonen M, Ketola I, Parviainen H, Pusa AK, Heikinheimo M. FOG-2 and GATA-4 Are coexpressed in the mouse ovary and can modulate mullerian-inhibiting substance expression. *Biol Reprod*. 2003;68:1333–40.
73. Taieb J, Grynberg M, Pierre A, Arouche N, Massart P, Belville C, et al. FSH and its second messenger cAMP stimulate the transcription of human anti-mullerian hormone in cultured granulosa cells. *Mol Endocrinol*. 2011;25:645–55.
74. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, et al. Mullerian inhibiting substance type II receptor (MISIR): a novel, tissue-specific target expressed by gynecologic cancers. *Gynecol Oncol*. 2008;108:141–8.
75. Farkkila A, Koskela S, Bryk S, Alfthan H, Butzow R, Leminen A, et al. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors-A comparative study with inhibin B. *Int J Cancer*. 2015;137:1661–71.
76. Edson MA, Nalam RL, Clementi C, Franco HL, Demayo FJ, Lyons KM, et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. *Mol Endocrinol*. 2010;24:1251–66.
77. Anttonen M, Farkkila A, Tauriala H, Kauppinen M, Maclaughlin DT, Unkila-Kallio L, et al. Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis. *Lab Invest*. 2011;91:1605–14.
78. Pepin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, et al. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. *Proc Natl Acad Sci USA*. 2015;112:E4418–27.
79. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003;9:669–76.
80. Farkkila A, Pihlajoki M, Tauriala H, Butzow R, Leminen A, Unkila-Kallio L, et al. Serum Vascular Endothelial Growth Factor A (VEGF) Is Elevated in Patients with Ovarian Granulosa Cell Tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. *J Clin Endocrinol Metab*. 2011;96:E1973–81.
81. Tsoi M, Lague MN, Boyer A, Paquet M, Nadeau ME, Boerboom D. Anti-VEGFA therapy reduces tumor growth and extends survival in a murine model of ovarian granulosa cell tumor. *Transl Oncol*. 2013;6:226–33.
82. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23: vii20–6.
83. Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, et al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. *Gynecol Oncol*. 2010;119:285–90.
84. Ertas IE, Gungorduk K, Taskin S, Akman L, Ozdemir A, Goklu R, et al. Prognostic predictors and spread patterns in adult ovarian granulosa cell tumors: a multi-center long-term follow-up study of 108 patients. *Int J Clin Oncol*. 2014;19:912–20.
85. Chua TC, Iyer NG, Soo KC. Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. *J Gynecol Oncol*. 2011;22:214–7.
86. Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. *Cancer Treat Rev*. 2008;34:1–12.
87. Park JY, Jin KL, Kim DY, Kim JH, Kim YM, Kim KR, et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. *Gynecol Oncol*. 2012;125:80–6.
88. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal

- malignancies: a Gynecologic Oncology Group study. *Gynecol Oncol.* 1999;72:131–7.
89. van Meurs HS, Buist MR, Westermann AM, Sonke GS, Kenter GG, van der Velden J. Effectiveness of chemotherapy in measurable granulosa cell tumors. A retrospective study and review of literature. *Int J Gynecol Cancer.* 2014;24:496–505.
 90. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. *Gynecol Oncol.* 2005;97:489–96.
 91. van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: a systematic review. *Gynecol Oncol.* 2014;134:196–205.
 92. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med.* 2011;365:2484–96.
 93. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. *Cancer.* 2014;120:344–51.
 94. National Comprehensive Cancer Network (NCCN) [Internet]. 2012 [cited 15 May 2012]. Available from: <http://www.nccn.org/>.
 95. Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors. *Int J Gynecol Cancer.* 2009;19:847–55.
 96. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. *J Clin Endocrinol Metab.* 1996;81:1401–5.
 97. Mom CH, Engelen MJ, Willemse PH, Gietema JA, ten Hoor KA, de Vries EG, et al. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. *Gynecol Oncol.* 2007;105:365–72.
 98. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet.* 2010;376:1155–63.
 99. Fleming ND, Cass I, Walsh CS, Karlan BY, Li AJ. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. *Gynecol Oncol.* 2011;121:249–52.